Brokerages Anticipate Voyager Therapeutics Inc (VYGR) Will Post Quarterly Sales of $2.90 Million
Equities research analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce $2.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Voyager Therapeutics’ earnings. The highest sales estimate is $5.00 million and the lowest is $2.00 million. Voyager Therapeutics reported sales of $6.35 million in the same quarter last year, which indicates a negative year over year growth rate of 54.3%. The business is expected to report its next quarterly earnings report on Wednesday, March 13th.
On average, analysts expect that Voyager Therapeutics will report full-year sales of $8.86 million for the current financial year, with estimates ranging from $7.61 million to $11.15 million. For the next year, analysts anticipate that the company will report sales of $23.08 million, with estimates ranging from $8.00 million to $68.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.15. The firm had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $3.02 million. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%.
NASDAQ VYGR traded down $0.16 during trading hours on Friday, reaching $9.10. The company’s stock had a trading volume of 185,000 shares, compared to its average volume of 251,065. The stock has a market cap of $307.99 million, a price-to-earnings ratio of -3.45 and a beta of 2.73. Voyager Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $31.91.
A number of large investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC lifted its holdings in Voyager Therapeutics by 7.9% in the 3rd quarter. Teachers Advisors LLC now owns 49,465 shares of the company’s stock valued at $936,000 after purchasing an additional 3,621 shares in the last quarter. Vanguard Group Inc lifted its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after purchasing an additional 113,442 shares in the last quarter. Marshall Wace LLP purchased a new position in Voyager Therapeutics in the 3rd quarter valued at about $1,112,000. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after purchasing an additional 113,442 shares in the last quarter. Finally, Standard Life Aberdeen plc purchased a new position in Voyager Therapeutics in the 3rd quarter valued at about $660,000. Institutional investors own 88.57% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Read More: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.